Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26639
Title: | T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection. | Austin Authors: | Kuzich, James A;Kankanige, Yamuna;Guinto, Jerick;Ryland, Georgina;McBean, Michelle;Wong, Eric ;Koldej, Rachel;Collins, Jenny;Westerman, David;Ritchie, David;Blombery, Piers | Affiliation: | Clinical Haematology Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia University of Melbourne, Parkville, VIC, Australia Clinical Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, VIC, Australia ACRF Translational Research Laboratory, Royal Melbourne Hospital, Parkville, VIC, Australia |
Issue Date: | Oct-2021 | Date: | 2021-05-24 | Publication information: | Bone Marrow Transplantation 2021; 56(10): 2582-2590 | Abstract: | Identification of patients at risk of initial & recurrent cytomegalovirus (CMV) reactivation following allogeneic stem cell transplant (alloSCT) may help guide prophylactic strategies. T-cell receptor beta (TRB) deep sequencing was used to identify and enumerate the T-cell repertoire harbouring TRB sequences with annotated specificity to CMV (pubCMVrep), as well as the overall T-cell receptor (TCR) repertoire diversity at day +30 & day +60 post-alloSCT for 65 patients. T-cells harbouring TRB sequences with annotated specificity for CMV were identifiable in all patients. 56% of patients required CMV treatment and 23% of the cohort developed recurrent CMV. PubCMVrep size at day +30 was not associated with reactivation, however amongst patients with antecedent CMV viremia a low day +60 pubCMVrep was associated with a greater incidence of recurrent CMV (75% vs. 21%, HR 6.16, 95% CI 1.29-29.40, P = 0.0008). Moreover, patients with high pubCMVrep only developed recurrent CMV in the setting of GVHD. Low TCR diversity at day +30 was associated with a greater incidence of initial CMV reactivation (71% vs. 22%, HR 5.39, 95% CI 1.70-17.09, p = 0.0002). pubCMVrep and TCR diversity are promising biomarkers to identify patients at risk of initial & recurrent CMV who may benefit from novel prophylactic strategies. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26639 | DOI: | 10.1038/s41409-021-01354-2 | ORCID: | 0000-0002-3657-8010 0000-0002-1627-8934 |
Journal: | Bone Marrow Transplantation | PubMed URL: | 34031553 | Type: | Journal Article | Subjects: | T cell receptor allogeneic stem cell transplant cytomegalovirus |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.